Projects per year
My line of research focuses on antidrug antibodies against therapeutic factor VIII (i.e. inhibitors) in persons with hemophilia. Nowadays advanced treatment and even gene therapy are available for this congenital bleeding disorder. However, this is not attainable for children who develop inhibitors. Immune tolerance induction therapy to eradicate inhibitors is only effective in a subset of patients.
I initiated an international multicenter cohort study to identify genetic and non-genetic determinants of achieving immune tolerance after immune tolerance induction therapy. Furthermore, to gain more insight in the pathophysiology of factor VIII specific immune tolerance we study factor VIII specific dendritic and T cell responses in persons who did and who did not achieve immune tolerance.
I have a great interest in research on value based health care and E-health innovations to improve treatment outcomes for persons living with hemophilia. I designed and set up a nationwide study on clinical and psychosocial health outcomes, including a biobank. Now I follow the national hemophilia population in a hemophilia patient registry. To further improve data collection and data exchange for both individuals’ care as well as data driven research, we are developing a personalized health record.
Collaborations and top research areas from the last five years
Dive into details
Select a country/territory to view shared publications and projects
AUTHOR GROUP, 2013, In: New England journal of medicine. 368, 3, p. 231-239
Research output: Contribution to journal › Article › Academic › peer-review356 Citations (Scopus)
Prevalence and incidence of non-neutralizing antibodies in congenital hemophilia a—a systematic review and meta-analysisAbdi, A., Bordbar, M. R., Hassan, S., Rosendaal, F. R., van der Bom, J. G., Voorberg, J., Fijnvandraat, K. & Gouw, S. C., 2020, In: Frontiers in immunology. 11, 563.
Research output: Contribution to journal › Article › Academic › peer-reviewOpen Access11 Citations (Scopus)
Treatment-related risk factors for inhibitor development in non-severe hemophilia A after 50 cumulative exposure days: A case-control studythe INSIGHT Study Group, Sept 2021, In: Journal of thrombosis and haemostasis. 19, 9, p. 2171-2181 11 p.
Research output: Contribution to journal › Article › Academic › peer-reviewOpen Access6 Citations (Scopus)
Hassan, S., van Balen, E. C., Smit, C., Mauser-Bunschoten, E. P., van Vulpen, L. F. D., Eikenboom, J., Beckers, E. A. M., Hooimeijer, L., Ypma, P. F., Nieuwenhuizen, L., Coppens, M., Schols, S. E. M., Leebeek, F. W. G., Driessens, M. H., Rosendaal, F. R., van der Bom, J. G. & Gouw, S. C., Oct 2021, In: Journal of thrombosis and haemostasis. 19, 10, p. 2394-2406 13 p.
Research output: Contribution to journal › Article › Academic › peer-reviewOpen Access17 Citations (Scopus)
Patient-relevant health outcomes for hemophilia care: Development of an international standard outcomes setvan Balen, E. C., O'Mahony, B., Cnossen, M. H., Dolan, G., Blanchette, V. S., Fischer, K., Gue, D., O'Hara, J., Iorio, A., Jackson, S., Konkle, B. A., Nugent, D. J., Coffin, D., Skinner, M. W., Smit, C., Srivastava, A., van Eenennaam, F., van der Bom, J. G. & Gouw, S. C., May 2021, In: Research and practice in thrombosis and haemostasis. 5, 4, e12488.
Research output: Contribution to journal › Article › Academic › peer-reviewOpen Access15 Citations (Scopus)